Companies › Phrontline Biopharma
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TJ101 EGFR/B7H3-directed antibody-drug conjugate with cleavable linker and novel topoisomerase I | EGFR, B7H3 | Phase 1 | Lung Cancer (NSCLC) | Dec 2026 |
| TJ102 CDH6/FRα directed antibody-drug conjugate with dual payloads | CDH6, FOLR1 | Phase 1 | Ovarian Cancer | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07181473 | TJ101 | Phase 1 | Lung Cancer (NSCLC) | Oncology | Dec 2026 |
| NCT07778498 | TJ102 | Phase 1 | Ovarian Cancer | Oncology | Sep 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.